Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1995 Jan;86(1):101–110. doi: 10.1111/j.1349-7006.1995.tb02994.x

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38

Yasutsuna Sasaki 1,2,✉, Hideo Hakusui 3, Shoichi Mizuno 4, Masashige Morita 2, Toshimichi Miya 2, Kenji Eguchi 2, Tetsu Shinkai 2, Tomohide Tamura 2, Yuichiro Ohe 2, Nagahiro Saijo 5
PMCID: PMC5920579  PMID: 7737901

Abstract

In the present study, an attempt was made to determine the precise pharmacokinetics of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin (CPT‐11) and its active metabolite, 7‐ethyl‐10‐hydroxycamptothecin (SN‐38). The relationship between pharmacokinetic parameters and pharmacodynamic effects was also investigated to elucidate the cause of interpatient variation in side effects. Thirty‐six patients entered the study. CPT‐11, 100 mg/m2, was administered by IV infusion over 90 min weekly for four consecutive weeks. The major dose‐limiting toxicities were leukopenia and diarrhea. There was a positive correlation between the area under the concentration‐time curve (AUC) of CPT‐11 and percent decrease of WBC (r=0.559). On the other hand, episodes of diarrhea had a better correlation with the AUC of SN‐38 (r=0.606) than that of CPT‐11 (r=0.408). Multivariate analysis revealed that the AUC of SN‐38, AUC of CPT‐11 and indocyanine green retention test were significant variables for the incidence of diarrhea and that both performance status and AUC of CPT‐11 were significant variables for percent decrease of WBC. The large interpatient variability of the degree of leukopenia and diarrhea is due to a great plasma pharmacokinetic variation in CPT‐11 or SN‐38. The AUCs of CPT‐11 and SN‐38 obtained from the first administration of CPT‐11 correlate with toxicities, but it is impossible to predict severe side effects before the administration of CPT‐11 at the present time.

Keywords: CPT‐11, SN‐38, Pharmacokinetics, Pharmacodynamics, AUC

Full Text

The Full Text of this article is available as a PDF (565.3 KB).

REFERENCES

  • 1. ) Wall , M. E. , Wani , M. C. , Cook , C. E. , Palmer , K. H. , McPhail , A. T. and Sim , G. A.Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibition from Camptotheca accuminata . J. Am. Chem. Soc. , 88 , 3888 – 3890 ( 1966. ). [Google Scholar]
  • 2. ) Gallo , R. C. , Whang‐Peng , J. and Adamson , R. H.Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin . J. Natl. Cancer Inst. , 46 , 789 – 795 ( 1971. ). [PubMed] [Google Scholar]
  • 3. ) Drewinko , B. , Freireich , E. J. and Gottlieb , J. A.Lethal activity of camptothecin sodium on human lymphoma cell . Cancer Res. , 34 , 747 – 750 ( 1974. ). [PubMed] [Google Scholar]
  • 4. ) Gottlieb , J. A. , Guarino , A. M. , Call , J. B. , Oliverio , V. T. and Block , J. B.Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC‐100880) . Cancer Chemother. Rep. , 54 , 461 – 470 ( 1970. ). [PubMed] [Google Scholar]
  • 5. ) Gottlieb , J. A. and Luce , J. K.Treatment of malignant melanoma with camptothecin (NSC‐100880) . Cancer Chemother. Rep. , 56 , 103 – 105 ( 1972. ). [PubMed] [Google Scholar]
  • 6. ) Muggia , F. M. , Creaven , P. J. , Hansen , H. H. , Cohen , M. H. and Selawry , O. S.Phase I clinical trial of weekly and daily treatment with camptothecin (NSC‐100880): correlation with preclinical studies . Cancer Chemother. Rep. , 56 , 515 – 521 ( 1972. ). [PubMed] [Google Scholar]
  • 7. ) Moertel , C. G. , Schutt , A. J. , Reitemeier , R. J. and Hahn , R. G.Phase II study of camptothecin (NSC‐100880) in the treatment of advanced gastrointestinal cancer . Cancer Chemother. Rep. , 56 , 95 – 101 ( 1972. ). [PubMed] [Google Scholar]
  • 8. ) Schaeppi , U. , Freischman , R. W. and Cooney , D. A.Toxicity of camptothecin (NSC‐100880) . Cancer Chemother. Rep. Part 3 , 5 , 25 – 36 ( 1974. ). [PubMed] [Google Scholar]
  • 9. ) Nagata , H. , Kaneda , N. , Furuta , T. , Sawada , S. , Yokokura , T. , Miyasaka , T. , Fukuda , M. and Notake , K.Action of 7‐ethylcamptothecin on tumor cells and its disposition in mice . Cancer Treat. Rep. , 71 , 341 – 348 ( 1987. ). [PubMed] [Google Scholar]
  • 10. ) Kunimoto , T. , Nitta , K. , Tanaka , T. , Uehara , N. , Baba , H. , Takeuchi , M. , Yokokura , T. , Sawada , S. , Miyasaka , T. and Mutai , M.Antitumor activity of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors . Cancer Res. , 47 , 5944 – 5947 ( 1987. ). [PubMed] [Google Scholar]
  • 11. ) Kanzawa , F. , Sugimoto , Y. , Minato , K. , Kasahara , K. , Bungo , M. , Nakagawa , K. , Fujiwara , Y. , Liu , L. F. and Saijo , N.Establishment of a camptothecin analogue (CPT‐11)‐resistant cell line of human non‐small cell lung cancer: characterization and mechanism of resistance . Cancer Res. , 50 , 5919 – 5924 ( 1990. ). [PubMed] [Google Scholar]
  • 12. ) Negoro , S. , Fukuoka , M. , Masuda , N. , Takada , M. , Kusunoki , Y. , Matsui , K. , Takifuji , N. , Kudoh , S. , Niitani , H. and Taguchi , T.Phase I study of weekly intravenous infusion of CPT‐11, a new derivative of camptothecin, in the treatment of advanced non‐small‐cell lung cancer . J. Natl. Cancer Inst. , 83 , 1164 – 1168 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Fukuoka , M. , Niitani , H. , Suzuki , A. , Motomiya , M. , Hasegawa , K. , Nishiwaki , Y. , Kuriyama , T. , Ariyoshi , Y. , Negoro , S. , Masuda , N. , Nakajima , S. and Taguchi , T.A phase II study of CPT‐11, a new derivative of camptothecin, for previously untreated non‐small‐cell lung cancer . J. Clin. Oncol. , 10 , 16 – 20 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Ohno , R. , Okada , K. , Masaoka , T. , Kuramoto , A. , Arima , T. , Yoshida , Y. , Ariyoshi , H. , Ichimaru , M. , Sakai , Y. , Oguro , M. , Ito , Y. , Morishima , Y. , Yokomaku , S. and Ohta , K.An early phase II study of CPT‐11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma . J. Clin. Oncol. , 8 , 1907 – 1912 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Takeuchi , S. , Noda , K. and Yakushiji , M.Late phase II study of CPT‐11, camptothecin derivative, in advanced cervical carcinoma . Proc. Am. Soc. Clin. Oncol. , 11 , 224 ( 1992. ). [Google Scholar]
  • 16. ) Takeuchi , S. , Takamizawa , H. , Takeda , Y. , Okawa , T. , Tamaya , Y. , Noda , K. , Sagawa , T. , Sekiba , K. , Yakushiji , M. and Taguchi , T.Clinical study of CPT‐11, camptothecin derivative, on gynecological malignancy . Proc. Am. Soc. Clin. Oncol. , 10 , 189 ( 1991. ). [Google Scholar]
  • 17. ) Shimada , Y. , Yoshino , M. , Wakui , A. , Nagao , I. , Futatsuki , K. , Sakata , Y. , Kambe , M. , Toguchi , T. , Ogawa , N.and the CPT‐11 Gastrointestinal Cancer Study Group.Phase II study of CPT‐11, a new camptothecin derivative, in metastatic colorectal cancer . J. Clin. Oncol. , 11 , 909 – 913 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Kaneda , N. and Yokokura , T.Nonlinear pharmacokinetics of CPT‐11 in rats . Cancer Res. , 50 , 1721 – 1725 ( 1990. ). [PubMed] [Google Scholar]
  • 19. ) Kaneda , N. , Nagata , H. , Furuta , T. and Yokokura , T.Metabolism and pharmacokinetics of camptothecin analogue CPT‐11 in the mouse . Cancer Res. , 50 , 1715 – 1720 ( 1990. ). [PubMed] [Google Scholar]
  • 20. ) Kawato , Y. , Aonuma , M. , Hirota , Y. , Kuga , H. and Sato , K.Intracellular roles of SN‐38, a metabolite of camptothecin derivative CPT‐11, in the antitumor effect of CPT‐11 . Cancer Res. , 51 , 4187 – 4191 ( 1991. ). [PubMed] [Google Scholar]
  • 21. ) Tsuji , T. , Kaneda , N. , Kado , K. , Yokokura , T. , Yoshimoto , T. and Tsuru , D.CPT‐11 converting enzyme from rat serum: purification and some properties . J. Pharmacobio-Dyn. , 14 , 341 – 349 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Oken , M. , Creech , R. , Tormey , D. , Horton , J. , Davis , T. E. , McFradden , E. T. and Carbone , P. P.Toxicity and response criteria of the Eastern Cooperative Oncology Group . Am. J. Clin. Oncol. , 5 , 649 – 655 ( 1982. ). [PubMed] [Google Scholar]
  • 23. ) Yamaoka , K. , Tanigawara , Y. , Nakagawa , T. and Uno , T.A pharmacokinetic analysis program (MULTI) for micro‐computer . J. Pharmacobio-Dyn. , 4 , 879 – 885 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Kudo , S. , Fukuoka , M. , Masuda , N. , Kusunoki , Y. , Matui , K. , Negoro , S. , Takifuji , N. , Nakagawa , K. , Hirashima , T. , Tamanoi , M. , Nitta , T. , Yana , H. and Takada , M.Relationship between CPT‐11 pharmacokinetics and diarrhea in the combination chemotherapy of irinotecan (CPT‐11) and cisplatin (CDDP) . Proc. Am. Soc. Clin. Oncol. , 12 , 141 ( 1993. ). [Google Scholar]
  • 25. ) Rowinsky , E. K. , Grochow , L. B. , Hendricks , C. B. , Ettinger , D. S. , Farastiere , A. A. , Hurowitz , L. A. , Sartorius , S. E. , Lubejko , B. G. , Kaufmann , S. H. and Donohowere , R. C.Phase I and pharmacology study of topotecan: a novel topoisomerase I inhibitor . J. Clin. Oncol. , 10 , 647 – 656 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Grochow , L. B. , Rowinsky , E. K. , Johnson , R. , Ludeman , S. , Kaufmann , S. H. , McCabe , F. L. , Smith , B. R. , Hurowitz , L. , DeLisa , A. , Donohour , R. C. and Noe , D. A.Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer . Drug Metab. Dispos. , 20 , 706 – 712 ( 1992. ). [PubMed] [Google Scholar]
  • 27. ) Sasaki , Y. , Yoshida , Y. , Sudoh , K. , Hakusui , H. , Fujii , H. , Ohtsu , T. , Wakita , H. , Igarashi , T. and Itoh , K.Pharmacological correlation between total drug concentration and lactones of CPT‐11 and SN‐38 in patients treated with CPT‐11 . Jpn. J. Cancer Res. , 86 , 111 – 116 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. ) Rothenberg , M. L. , Kuhn , J. G. , Burris , H. A. , III , Nelson , J. , Eckardt , J. R. , Tristan‐Morales , M. , Hilsenbeck , S. G. , Weiss , G. R. , Smith , L. S. , Rodriguez , G. I. , Rock , M. K. and Von Hoff , D. D.Phase I and pharmacokinetic trial of weekly CPT‐11 . J. Clin. Oncol. , 11 , 2194 – 2204 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Rowinsky , E. K. , Grochow , L. B. , Ettinger , D. S. , Sartorius , S. E. , Lubejko , B. G. , Chen , T.‐L. , Rock , M. K. and Donehowere , R. C.Phase I and pharmacological study of novel topoisomerase I inhibitor 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino]carbonyloxycamptothecin (CPT‐11) administered as a ninety‐minute infusion every 3 weeks . Cancer Res. , 54 , 427 – 436 ( 1994. ). [PubMed] [Google Scholar]
  • 30. ) Houghton , P. J. , Cheshire , P. J. , Hallman , J. C. , Bissery , M. C. , Mathieu‐Bou'e , A. and Houghton , J. A.Therapeutic efficacy of the topoisomerase I inhibitor 7‐ethyl‐10‐(4‐[1‐piperidino]‐1‐piperidino] carbonyloxycamptothecin against human tumor xenografts: lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9‐dimethylaminomethyl‐10‐hydroxycamptothecin . Cancer Res. , 53 , 2823 – 2829 ( 1993. ). [PubMed] [Google Scholar]
  • 31. ) Negoro , S. , Fukuoka , M. , Masuda , N. , Kusunoki , Y. , Matui , K. , Kudoh , S. , Takifuji , N. , Nakagawa , K. , Hirashima , T. , Tamanoi , M. , Nitta , T. , Yana , H. and Takada , M.Phase I study of irinotecan (CPT‐11) and etoposide (E) with g‐CSF in advanced lung cancer . Proc. Am. Soc. Clin. Oncol. , 12 , 133 ( 1993. ). [Google Scholar]
  • 32. ) Shimada , Y. , Sasaki , Y. , Sugano , K. , Shirao , K. , Kondo , H. , Yokota , T. , Saito , D. , Tamura , T. , Ohe , Y. , Shinkai , T. , Eguchi , K. , Saijo , N. and Shintani , S.Combination phase I study of CPT‐11 (irinotecan) combined with continuous infusion of 5‐fluorouracil (5‐FU) in metastatic colorectal cancer . Proc. Am. Soc. Clin. Oncol. , 12 , 196 ( 1993. ). [Google Scholar]
  • 33. ) Karato , A. , Sasaki , Y. , Shinkai , T. , Eguchi , K. , Tamura , T. , Ohe , Y. , Oshita , F. , Nishio , M. , Kunikane , H. , Arioka , H. , Ohmatsu , H. , Nakashima , H. , Shiraishi , J. and Saijo , N.Phase I study of CPT‐11 and etoposide in patients with refractory tumors . J. Clin. Oncol. , 11 , 2030 – 2035 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 34. ) Abigerges , D. , Armand , P. J. , Chabot , G. G. , Costa , L. D. , Fadel , E. , Cote , C. , H'erait , P. and Gandia , D.Irinotecan (CPT‐11) high‐dose escalation using intensive high‐dose loperamide to control diarrhea . J. Natl. Cancer Inst. , 86 , 446 – 449 ( 1994. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES